Key result
This review investigated the cardiotoxic side effects of targeted chemotherapeutic agents, such as monoclonal antibodies and small molecules, in pediatric cancer patients.
Why the study?
Targeted cancer therapies used alone or with conventional chemotherapy are linked to cardiovascular adverse events mostly reported in adults, leaving their cardiotoxic effects in pediatric patients to be reviewed.
This review highlights the potential for cardiotoxic side effects associated with emerging targeted therapies in pediatric cancer patients.
Warrants heightened clinical vigilance for cardiotoxicity during novel pediatric oncology treatments;.
Cardiotoxicity represents an important acute or chronic adverse event of treatment modalities for childhood cancer. In the last two decades the emergence of novel cancer therapies has aimed to increase unaided or mostly in combination with conventional chemotherapy for the survival rates of pediatric cancer especially for those patients with relapsed and/or refractory disease. The use of emerging targeted therapies in combination with conventional chemotherapy is related to cardiovascular adverse events mostly reported in adults. The aim of our short review was to investigate the cardiotoxic side effects of targeted chemotherapeutic agents as monoclonal antibodies and small molecules in pediatric cancer patients.
No takes yet. Share an insight, caveat, or question.
Bangeas et al. (2023) conducted a review in Childhood cancer (haematological malignancies and solid tumors). Targeted therapies (monoclonal antibodies and small molecules) was evaluated on Cardiotoxic side effects. This review investigated the cardiotoxic side effects of targeted chemotherapeutic agents, such as monoclonal antibodies and small molecules, in pediatric cancer patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: